Author:
Amegadzie Joseph Emil,Gamble John-Michael,Farrell Jamie,Gao Zhiwei
Abstract
Abstractβ2-agonists provide necessary bronchodilatory action, are recommended by existing clinical practice guidelines and are widely prescribed for patients with these conditions. We examined the risk of all-cause mortality and hospitalization for pneumonia associated with long-or short-acting β2-agonists (LABA or SABA) or ICS (inhaled corticosteroids)/LABA use. In a nested case–control of 185,407 patients, we found no association between β2-agonist use and the risk of pneumonia in patients with asthma, COPD, or asthma-COPD overlap. In contrast, new SABA [HR 1.82 (95% CI 1.04–3.20)] or LABA [HR 2.77 (95% CI 1.22–6.31)] use was associated with an increased risk of all-cause mortality compared to ICS use in COPD patients.
Funder
Canadian Respiratory Research Network
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5(S1):S7–10. https://doi.org/10.1002/alr.21547.
2. Hurst JR, Siddiqui MK, Singh B, Varghese P, Holmgren U, de Nigris E. A systematic literature review of the humanistic burden of COPD. Int J Chronic Obstr Pulm Dis. 2021;16:1303–14. https://doi.org/10.2147/COPD.S296696.
3. Hosseini M, Almasi-Hashiani A, Sepidarkish M, Maroufizadeh S. Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respir Res. 2019;20(1):229–229. https://doi.org/10.1186/s12931-019-1198-4.
4. GINA, Global Initiative for Asthma, 2022 update. Published online December 29, 2021. https://ginasthma.org/gina-reports/
5. GOLD. COPD guidelines. Published online April 7, 2022. https://goldcopd.org/2022-gold-reports-2/